Subtype
Colorectal Carcinoma
CI-CAN-00005005CRCExplore in graph →
344 active trials5 approved drugs22 evidence items
- NCIt
- C2955
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005005CRCExplore in graph →
Clinical trials
1,010 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (127)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06882746 | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas | terminated | Phase 1 | 14 | Boehringer IngelheimINDUSTRY | 3 | Sep 24, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05514717 |
| A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 |
| terminated |
| Phase 1 |
| 57 |
| Day One Biopharmaceuticals, Inc.INDUSTRY |
| 1 |
| Jun 18, 2026 |
| clinicaltrials |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers | terminated | Phase 1 | 17 | Accent TherapeuticsINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | terminated | Phase 1 | 9 | PfizerINDUSTRY | 3 | Sep 17, 2025 | clinicaltrials |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | terminated | Phase 1 / Phase 2 | 175 | Bolt Biotherapeutics, Inc.INDUSTRY | 4 | Sep 15, 2025 | clinicaltrials |
| NCT04645797 | A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions | terminated | Phase 1 | 11 | Apros Therapeutics, IncINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT04108481 | Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer(iRE-C) | terminated | Phase 1 | 5 | University of IowaOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04406857 | Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer | terminated | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | terminated | Phase 1 | 8 | Incyte CorporationINDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | terminated | Phase 1 | 13 | Biomea Fusion Inc.INDUSTRY | 2 | Feb 7, 2025 | clinicaltrials |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT03300544 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer | terminated | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | May 23, 2024 | clinicaltrials |
| NCT04808362 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours(MYCure) | terminated | Phase 1 / Phase 2 | 22 | Peptomyc S.L.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT01545141 | Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer | terminated | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT04044430 | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | terminated | Phase 1 | 2 | University of California, San FranciscoOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | terminated | Phase 1 / Phase 2 | 2 | Silverback TherapeuticsINDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer | terminated | Phase 1 | 4 | Fox Chase Cancer CenterOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | terminated | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT03029988 | An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases. | terminated | Phase 1 | 3 | Navidea BiopharmaceuticalsINDUSTRY | 1 | Sep 10, 2020 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT01197664 | Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery | terminated | Phase 1 | 2 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02577588 | Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer(ATACC) | terminated | Phase 1 | 1 | National Center for Tumor Diseases, HeidelbergOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT02110953 | Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver | terminated | Phase 1 | 2 | Fox Chase Cancer CenterOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT00361244 | SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | terminated | Phase 1 / Phase 2 | 6 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT01937715 | A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 18 | PfizerINDUSTRY | 3 | Aug 18, 2016 | clinicaltrials |
| NCT01111292 | Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 12, 2016 | clinicaltrials |
| NCT01816659 | An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01198535 | Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer | terminated | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | May 18, 2015 | clinicaltrials |
| NCT00002796 | Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00288444 | Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer | terminated | Phase 1 | 38 | Emory UniversityOTHER | 1 | Dec 18, 2012 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials